Testimonials

Practices that have diversified into managing AMD are some of the most successful in the country and are well-positioned for the future.

Paul Karpecki, OD

Having been a Vision Source Administrator for nearly 15 years, I know the mindset of the prototypical Vision Source doctor, and it is this: seek out and deliver the highest outcome patient care using the most up-to-date technology that is based on the latest peer-reviewed research. While accomplishing this worthy goal, the Vision Source doctor also watches to be certain that this increased level of care will simultaneously enhance the practice’s business well-being and also save money for the overall health care system with early diagnosis and treatment. Having also been trained extensively on dark adaptometry technology, I can wholeheartedly say that the AdaptDx instrument checks every single box for the Vision Source practitioner to accomplish all of these patient goals in the early detection and treatment of subclinical AMD.

Perry Lopez, OD

The research behind the AdaptDx is solid. Its specificity and sensitivity are better than a visual field for glaucoma. And macular degeneration is 3 times more prevalent then glaucoma and diabetic retinopathy combined. So why would I not use the AdaptDx test on everybody over the age of 50? Oh, and did I mention it catches subclinical AMD before you can see drusen or mottling in the eye itself?

Ryan LeBreton, OD

I am excited that my practice can now work toward the goal of eliminating vision loss from macular degeneration by proactively identifying this disease early and providing earlier intervention for our patients. Our AdaptDx sits next to our visual field and OCT. Our practice is now prepared to identify and manage macular degeneration the same way we do glaucoma.

Ryan Powell, OD

After learning the specifics about pre-clinical macular degeneration and the opportunity I have to identify this devastating disease in my patients much earlier than ever before, it was a no-brainer that all my patients with risk factors or over the age of 50 must have the AdaptDx test done.

Ryan Powell, OD

The MacuLogix AdaptDx dark adaptometer is the first device of its kind that will provide me with a quantifiable result that can be monitored over time. It allows me to track the function of a patient’s macular rod photoreceptors, which is a very specific biomarker for AMD. In my opinion, this device is a game-changer in any practice committed to preserving sight. Having the ability to diagnose AMD in patients with symptoms but little to no clinical signs has taken my confidence to the next level.

Timothy Earley, OD

I strongly believe that if we can catch AMD at a very early stage and be really proactive with recommending supplements, blue light filters, sunglasses, telling them to watch their BMI, their cholesterol levels, that we can stop or slow this down and maintain their vision the rest of their life.

Laurie Sorrenson, OD, FAAO

Our doctors decided that we should be doing an AMD screening for our patients over the age of 65 no matter what. Photos and looking at the macula is just not enough. If you look at the statistics, it makes more sense to do an AdaptDx test on this population than it does to take a tonometry reading to screen for glaucoma!! We decided we wanted to be more proactive and take better care of our patients. Using the AdaptDx to find subclinical AMD enables us to do just that.

Laurie Sorrenson, OD, FAAO

Equipment companies usually ship you a big box and you never hear from them again. That was not the case with MacuLogix and their AdaptDx. They spent 2 days with us and did a fantastic job training our whole office!

Julia Blank, OD

AdaptDx more than paid for itself within the first few months.

Tammy Tully, OD